Price Alert

Concert Pharmaceuticals I... (CNCE)

NASDAQ: CNCE · Real-Time Price · USD

8.37

0.00 (0.00%)

At close: Mar 03, 2023, 10:00 PM

Concert Pharmaceuticals Statistics

Share Statistics

Concert Pharmaceuticals has 0 shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	43.66M
Failed to Deliver (FTD) Shares	1,186
FTD / Avg. Volume	0.05%

Short Selling Information

The latest short interest is 395.31K, so 0% of the outstanding shares have been sold short.

Short Interest	395.31K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -1.31 and the forward PE ratio is null. Concert Pharmaceuticals's PEG ratio is 0.

PE Ratio	-1.31
Forward PE	n/a
PS Ratio	3.33
Forward PS	n/a
PB Ratio	0.97
P/FCF Ratio	-1.96
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Concert Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.33, with a Debt / Equity ratio of 0.13.

Current Ratio	9.33
Quick Ratio	9.33
Debt / Equity	0.13
Debt / EBITDA	-0.21
Debt / FCF	-0.27
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$509.03K
Profits Per Employee	$-1.29M
Employee Count	64
Asset Turnover	0.2
Inventory Turnover	n/a

Taxes

Income Tax	2.54M
Effective Tax Rate	-3.18%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 0.52, so Concert Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.52
52-Week Price Change	n/a
50-Day Moving Average	7.49
200-Day Moving Average	5.99
Relative Strength Index (RSI)	66.67
Average Volume (20 Days)	2,542,039

Income Statement

In the last 12 months, Concert Pharmaceuticals had revenue of 32.58M and earned -82.59M in profits. Earnings per share was -2.4.

Revenue	32.58M
Gross Profit	32.58M
Operating Income	-77.51M
Net Income	-82.59M
EBITDA	-73.49M
EBIT	-77.51M
Earnings Per Share (EPS)	-2.4

Full Income Statement

Balance Sheet

The company has 141.64M in cash and 15.06M in debt, giving a net cash position of 126.57M.

Cash & Cash Equivalents	141.64M
Total Debt	15.06M
Net Cash	126.57M
Retained Earnings	-349.5M
Total Assets	171.13M
Working Capital	139.8M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -55.15M and capital expenditures -255K, giving a free cash flow of -55.41M.

Operating Cash Flow	-55.15M
Capital Expenditures	-255K
Free Cash Flow	-55.41M
FCF Per Share	-1.61

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -237.92% and -253.53%.

Gross Margin	100%
Operating Margin	-237.92%
Pretax Margin	-245.72%
Profit Margin	-253.53%
EBITDA Margin	-225.57%
EBIT Margin	-237.92%
FCF Margin	-170.08%

Dividends & Yields

CNCE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for CNCE.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	2.43
Piotroski F-Score	1